AstraZeneca Acquires AI Firm Modella to Boost Oncology Research
AstraZeneca has announced the acquisition of Modella AI, a Boston-based AI company, to enhance its oncology drug development. This marks the first time a major pharmaceutical company has acquired an AI firm, signaling a shift in the industry's approach to AI integration.
Insights:
In a groundbreaking move for the pharmaceutical industry, AstraZeneca PLC has announced its acquisition of Modella AI, a Boston-based artificial intelligence company. This acquisition, revealed on January 13, 2026, marks the first instance of a major pharmaceutical company acquiring an AI firm, highlighting a significant shift in how the industry approaches artificial intelligence integration. The financial terms of the deal were not disclosed.
The acquisition of Modella AI expands a multi-year collaboration between the two companies that began in July 2025. Modella's AI foundation models and agents will be integrated into AstraZeneca's oncology drug development, biomarker discovery, and clinical development efforts. This strategic move aims to accelerate the company's quantitative pathology capabilities and improve the selection process for patients in drug trials.
